Pharmabiz52m
SciSparc submits IND application to US FDA for phase IIb trial for Tourette syndrome
SciSparc submits IND application to US FDA for phase IIb trial for Tourette syndrome: Tel Aviv, Israel Friday, September 20, 2024, 17:30 Hrs [IST] SciSparc Ltd., a specialty clini ...
DermaSensor’s skin cancer detection device helps clinicians in published study
A sub-analysis of the study highlighted that the DermaSensor device effectively detects skin cancer across different skin ...
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky ...
The Free Press Journal on MSN1d
Indian Americans On Republican Vs Democrat Debate: Which Political Party Is Better For The Economy?
An objective study of the recent presidencies paints a ... federal agencies like the Occupational Safety and Health ...
FDA to propose new food label warnings to combat obesity
The FDA is considering food labels to help consumers identify products with unhealthy ingredients, but some experts wonder if ...
The FDA wants to place warning labels on food packages to combat obesity and other health conditions
The Food and Drug Administration (FDA) is looking to propose the inclusion of front-of-package warning labels that detail the ...
Cure Today2d
FDA Approves Keytruda Plus Chemo for Pleural Mesothelioma Subset
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...
FDA advisers unconvinced by Intercept's liver disease drug benefits, safety
Independent advisers to the U.S. Food and Drug Administration voted on Friday against confirmatory trial data for Intercept Pharmaceuticals' liver disease drug, putting into question the treatment's ...
Stockhead on MSN4d
Alive and Kicking: Respiri promises breath of life to bottom line after inking US distribution deal
Telehealth respiratory group Respiri says a sales deal with a US group will help the firm achieve cash-flow breakeven status ...
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept.
Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC
Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy ...
Armed robbery in Revesby4d
Alliance Unveils Phase III Cabozantinib Trial Results at ESMO
The Alliance for Clinical Trials in Oncology today announced final results will be presented at ESMO 2024 from CABINET ...